ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in KROS — Keros Therapeutics, Inc.
CIK 1164508
BOSTON, MA
Position in KROS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,494,972
-$4,021,376 QoQ
Shares Held
233,175
-60.5% QoQ
Ownership
1.18%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#22
of 131 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KROS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,519,535,758 across 72 Biotechnology names. KROS ranks #53 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
738,378 | $366,774,503 | |
| 2 | INCY |
Incyte Corp
|
2,744,958 | $311,168,438 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
393,685 | $245,478,344 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,365,926 | $237,550,033 | |
| 5 | GMAB |
Genmab A/S
|
4,975,324 | $136,672,150 | |
| 6 | RPRX |
Royalty Pharma plc
|
2,435,341 | $136,549,569 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
1,704,623 | $133,420,842 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
249,758 | $71,173,537 |
All Filings in KROS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,494,972 | 233,175 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $6,516,348 | 590,249 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $27,170,745 | 1,334,516 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $4,093,488 | 258,754 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $862,156 | 64,581 | Shares | Defined | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||